The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: TUI And Plus500 Both Rise Despite Profit Falls

Tue, 13th Aug 2019 08:43

(Alliance News) - Stock prices in London opened lower on Tuesday as concerns about the US-China trade war, protests in Hong Kong, and fears of a global economic slowdown continue to sap sentiment. The FTSE 100 was down 15.23 points, or 0.2%, at 7,211.49. The FTSE 250 was down 5.96 points at 18,907.04. The AIM All-Share was up 1.13 points, or 0.1%, at 875.44.The Cboe UK 100 index was down 0.4% at 12,219.61. The Cboe UK 250 was flat at 16,852.89. The Cboe UK Small Companies was flat at 10,928.12.In European equities, the CAC 40 in Paris was down 0.3% and the DAX 30 in Frankfurt down 0.4%. On the London Stock Exchange, TUI was the best blue-chip performer at the open, up 3.5% after the Anglo-German travel company reported revenue growth on strong performances by its experiences businesses in the third quarter. For the three months ended June, revenue rose 3.7% to EUR4.75 billion from EUR4.58 billion the year before. Revenue was supported by strong performances by the Destination Experiences, Holiday Experiences, and Cruises divisions. This was offset by weakness in the Western Region, Northern Region, and All Other Segments units.However, underlying earnings before interest, taxes & amortisation narrowed 46% to EUR100.9 million from EUR186.8 million a year prior. Profit performance was hurt by the Markets & Airlines unit sinking to a EUR103.9 million underlying Ebita loss from a EUR37.2 million profit the year prior. TUI said the third quarter was hurt by the grounding of the Boeing 737 MAX aircraft, 15 of which it had used within its holiday airline fleet, and it anticipates 737 MAX related costs of up to EUR300 million for the current financial year.TUI reiterated its full-year guidance for underlying Ebita to fall by up to 26% from last year."The overall picture is one which shows the benefits of a diversified business model. Its significant other income streams, most notably Holiday Experiences, Cruises and Destination Experiences have performed strongly in the year to date. in terms of the summer so far, bookings are virtually flat as compared to last year, which is some achievement given the circumstances and the outlook for the remainder of the summer is upbeat," said Interactive Investor analyst Richard Hunter. "TUI had the kitchen-sink experience earlier in the year with two profit warnings, so the fact that there are no further shocks has resulted in a warm share price reaction to these numbers," Hunter added. GlaxoSmithKline was up 1.0% after JPMorgan restarted coverage on the drugmaker with a Neutral rating. At the other end of the large cap index, Croda International was the worst performer, down 2.1% after Goldman Sachs cut the speciality chemicals company to Sell from Neutral. In the FTSE 250, Plus500 was the star performer, up 15% after the contract-for-difference provider said it has "performed well", despite reporting a steep drop in both revenue and profitability and slashing its dividend.Plus500's revenue for the six months to June fell 68% year-on-year to USD148.0 million, with pretax profit slumping 82% to USD63.9 million. Net profit fell 80% to USD51.6 million, with earnings before interest, taxes, depreciation, and amortisation down 81% to USD65.6 million.Plus500 will be returning USD0.2734 per share to shareholders for the period, an 80% reduction from the USD1.3786 paid out a year before. However, the firm also announced a share buyback worth USD50.0 million. The company said its half-year performance was in line with expectations, with the second quarter improving on the first after financial markets volatility increased. It said the second quarter was the strongest since new product regulations came into force in August 2018. At the other end of the large-cap index, Aston Martin Lagonda was the worst performer, down 6.0% after Credit Suisse downgraded the Valkyrie hypercar maker to Neutral from Outperform. The pound was quoted at USD1.2066 early Tuesday, soft against USD1.2071 at the London equities close Monday, ahead of UK jobless data at 0930 BST. Sterling hit a fresh two-year low of USD1.2014 on Monday.The UK unemployment rate is expected to remain at 3.8%."The pound will be back in focus for traders today as it tries to hold on above 1.20 against the dollar, despite the increased threat of no-deal Brexit and the turmoil that could bring. There may be a rare piece of good news today though as the labour market data is released. This has been a constant source of positive news for the economy and forecasts today suggest there could be more of the same," said OANDA analyst Craig Erlam.The Japanese Nikkei 225 index closed down 1.1% on Tuesday. In China, the Shanghai Composite closed down 0.6%, while the Hang Seng index in Hong Kong was down 1.7%. Financial markets in Japan reopened after being closed on Monday for the Mountain Day holiday.Increasing unrest in Hong Kong was hurting sentiment as protests extended into a third month, with the city's airport cancelling all flights in and out on Monday evening as thousands of demonstrators descended.In Tuesday's economic calendar, there is the US consumer price index at 1330 BST with the retail Redbook index due at 1355 BST.

More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.